Antibody Drug Conjugates Market (By Application: Blood Cancer, Breast Cancer; By Technology: Type-cleavable, Non-cleavable; By Product; By Target) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global antibody drug conjugates market size was valued at USD 11.32 billion in 2023 and is anticipated to reach around USD 27.42 billion by 2033, growing at a CAGR of 9.25% from 2024 to 2033.

Key Pointers

• North America led the global market with the largest market share of 53% in 2023.
• Asia Pacific antibody drug conjugate market is anticipated to witness significant growth from 2024 to 2033.
• By Application, the breast cancer segment held the largest revenue share of 48% in 2023.
• By Target, the HER2 (human epidermal growth factor receptor 2) target type segment generated the maximum market share in 2023.
• By Target, the CD22 target segment stands out as one of the fastest-growing segments over the forecast period.
• By Technology, the cleavable linker segment captured the maximum market share of 73% in 2023.

Antibody Drug Conjugates Market Overview

The antibody drug conjugates (ADCs) market is witnessing significant growth and innovation, driven by advancements in biotechnology and the rising demand for targeted cancer therapies. ADCs represent a promising class of anticancer drugs that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents, thereby offering improved efficacy and reduced systemic toxicity compared to traditional chemotherapy.

Antibody Drug Conjugates Market Growth Factors

The antibody drug conjugates (ADCs) market is experiencing robust growth, propelled by an increasing incidence of cancer worldwide underscores the urgent need for innovative treatment options, driving the demand for ADC therapies. Secondly, continuous advancements in biotechnology, including antibody engineering and payload design, have resulted in the development of next-generation ADCs with enhanced efficacy and safety profiles. Additionally, strategic collaborations between pharmaceutical companies and research institutions facilitate the accelerated development and commercialization of novel ADC candidates. Moreover, regulatory approvals for new ADC therapies by authorities such as the FDA and EMA have expanded market opportunities and improved patient access to these innovative treatments. Lastly, the growing acceptance of ADCs in clinical practice, coupled with reimbursement support, further fuels market growth.

U.S. Antibody Drug Conjugates Market Size 2024 to 2033

The U.S. antibody drug conjugates market was valued at USD 4.49 billion in 2023 and it is predicted to hit around USD 10.89 billion by 2033 with a CAGR of 9.25% from 2024 to 2033.

In the United States specifically, the antibody drug conjugate market is on the rise due to factors such as heightened awareness among healthcare professionals about ADCs, the availability of advanced ADCs, and substantial R&D investment by manufacturers. For example, in April 2021, Gilead received FDA approval for Trodelvy for treating adult patients with locally advanced or metastatic urothelial cancer. This approval for a new indication is expected to bolster the market for Trodelvy and drive sales of other ADC drugs such as Polivy, Padcev, and Enhertu over time.

In 2023, the North America antibody drug conjugate market held the largest revenue share at 53%. The market's growth is fueled by heightened awareness about ADCs among healthcare professionals and favorable reimbursement policies. Over the forecast period, North America is poised to experience significant growth, driven by increased awareness of current treatment therapies, favorable reimbursement policies, substantial R&D investment, and improved patient affordability. Key players operating in this region include Seagen, Inc.; F. Hoffmann La-Roche Ltd.; Gilead Sciences Inc.; and Pfizer Inc.

Meanwhile, the Asia Pacific antibody drug conjugate market is anticipated to witness significant growth over the forecast period, fueled by the presence of emerging economies, increasing investments in the biotechnology sector, improving government initiatives, and the rapidly growing clinical research and outsourcing markets. Additionally, enhancements in healthcare facilities and R&D in drug development are expected to further propel market growth in the region

Antibody Drug Conjugates Market Trends:

• Increased Research and Development: Companies are heavily investing in R&D to develop novel ADC candidates with improved efficacy and safety profiles.
• Targeted Therapies: Growing preference for targeted therapies, such as ADCs, over traditional chemotherapy due to their ability to selectively deliver cytotoxic agents to cancer cells while minimizing off-target toxicity.
• Combination Therapies: The exploration of combination therapies involving ADCs alongside other treatment modalities, such as immunotherapy and chemotherapy, to enhance efficacy and overcome drug resistance.
• Regulatory Approvals: Regulatory approvals for new ADC therapies by health authorities such as the FDA and EMA, facilitating market expansion and improving patient access to innovative treatments.
• Personalized Medicine: Growing emphasis on personalized medicine approaches, with ADCs offering the potential for targeted treatment tailored to individual patient characteristics and tumor profiles.
• Manufacturing Innovations: Efforts to address manufacturing complexities associated with ADC production, including optimizing conjugation processes and scaling up production to meet growing demand.

Application Insights

In 2023, the breast cancer segment took the lead in the market, holding a significant revenue share of 48%. This was primarily driven by various factors including the increasing incidence of breast cancer, the promising pipeline of products, and the widespread adoption of Kadcyla. Noteworthy products approved for breast cancer treatment include Trodelvy, Enhertu, and Kadcyla. The recent label expansion of Kadcyla to encompass early breast cancer patients, along with the recent approvals of Enhertu and Trodelvy, are anticipated to further propel the growth of this segment. Conversely, the blood cancer segment is poised to exhibit a high Compound Annual Growth Rate (CAGR) from 2024 to 2030.

Blood cancer ranks as the fifth most common cancer globally and stands as the second leading cause of cancer-related deaths. According to data from the National Foundation of Cancer Research, approximately 186,400 new cases of leukemia, lymphoma, and myeloma were diagnosed in the United States alone in 2022. Furthermore, market growth in this segment is expected to be fueled by the approval of multiple products throughout the forecast period. For instance, the introduction of Polivy in October 2019 for treating diffuse large B-cell lymphoma (DLBCL) is indicative of the advancements driving market expansion in the blood cancer arena.

Product Insights

In 2023, the Kadcyla segment emerged as the frontrunner in the ADC space, boasting the highest revenue. The surge in breast cancer cases, coupled with increased approvals for ADCs tailored specifically for breast cancer treatment, has been instrumental in driving the market's upward trajectory. A significant milestone was achieved when F. Hoffmann-La Roche Ltd. secured approval for Kadcyla in China's rapidly expanding industry in January 2022, marking a pivotal development.

A strategic maneuver was observed with Kadcyla in 2023, as Roche implemented a strategic price reduction of over 50% for the drug in China. This bold move aimed to capture a larger market share through competitive pricing. Notably, China, once Roche's 10th largest market, has now ascended to the second position. Roche's decision to adjust prices strategically underscores the dynamic shift in its market approach, aligning with the evolving landscape in China.

Enhertu stands out as one of the fastest-growing segments over the forecast period. Developed by DAIICHI SANKYO COMPANY, LIMITED. and AstraZeneca, Enhertu has experienced a surge in sales projections following recent approvals. Particularly noteworthy is its groundbreaking approval for HER2-low breast cancer in August 2022, marking an industry-first achievement. During a recent earnings call, Daiichi emphasized Enhertu's swift adoption in this new indication, catering to patients with tumors previously classified as HER2-negative. Additionally, since its launch for second-line HER2-positive breast cancer in May 2022, Enhertu has outperformed competitors, securing the largest share of new patients.

Target Insights

In 2023, the HER2 (human epidermal growth factor receptor 2) target type segment emerged as the leader in market share. HER2 holds pivotal significance, particularly in breast cancer treatment, where its overexpression is common. ADCs engineered to target HER2 function by delivering potent drugs directly to cancer cells, thereby minimizing damage to healthy cells and enhancing therapeutic efficacy. With high adoption rates attributed to such factors, the HER2 segment asserted its dominance in the industry.

The CD22 target segment stands out as one of the fastest-growing segments over the forecast period. This segment is notable for its widespread adoption in cancer therapy, particularly in leukemia indications, making it the fastest-growing niche within the space. The increasing demand for CD22-targeted therapies in leukemia is driven by their demonstrated efficacy and limited side effects, rendering them a preferred choice among healthcare professionals and patients alike.

Technology Insights

In 2023, the cleavable linker segment dominated the market, accounting for the largest revenue share at 73%. Cleavable linkers are favored for their ability to maintain stability in the bloodstream for extended periods and facilitate the controlled release of cytotoxins from ADCs, thereby enhancing the effectiveness of ADCs in cancer treatment. For example, Seagen’s and Takeda’s Adcetris, approved by the NMPA in 2020 for treating relapsed Hodgkin's lymphoma and relapsed systemic anaplastic large cell lymphoma sALCL in China, exemplifies the efficacy of cleavable linkers. Such factors are expected to drive further growth in the cleavable linker segment.

Following closely, the non-cleavable linker segment emerged as the second-largest revenue generator in 2023, primarily due to the increased usage of Kadcyla, which incorporates a non-cleavable linker. Non-cleavable linkers are utilized in the production of ADCs that rely on lysosomal degradation, preventing nonspecific drug release and reducing overall cytotoxicity to surrounding healthy cells. This characteristic is anticipated to fuel growth in the segment. Currently, FDA-approved ADCs such as Kadcyla and Blenrep utilize non-cleavable linkers for binding the antibody and cytotoxic molecule.

Regarding payloads, these cytotoxic agents play a vital role in killing target cancer cells. Various payloads are available in the market, including microtubule inhibitors (such as Vinorelbine, Paclitaxel, Epothilone B, Tubulysins), DNA cleavers (like Bleomycin A2), Akt inhibitors (such as GDC-0068), DNA intercalators (including Doxorubicin hydrochloride, Epirubicin hydrochloride, Duocarmycins, PBD dimers), and MMAF & MMAE. For instance, Blenrep (belantamab mafodotin-blmf) developed by GlaxoSmithKline Plc., employs MMAF, protease linker, and anti-CD38 monoclonal antibody to target cells in adult patients with relapsed multiple myeloma.

Antibody Drug Conjugates Market Key Companies

• Seagen, Inc.
• Takeda Pharmaceutical Company Ltd.
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Gilead Sciences, Inc.
• Daiichi Sankyo Company Ltd.
• GlaxoSmithKline Plc
• Astellas Pharma, Inc.
• ADC Therapeutics SA

Recent Developments

• In January 2024, Celltrion, Inc., and WuXi XDC signed a Memorandum of Understanding (MOU) for integrated services for ADCs, encompassing the development and manufacturing of ADCs.
• In the same month, Jonhson & Johnson Services, Inc., acquired Ambrx Biopharma, Inc., which possesses proprietary ADC technology aimed at developing next-generation novel ADCs for cancer treatment. J&J's strategic focus lies on its prostate cancer portfolio while leveraging this proprietary technology.
• Additionally, in January 2024, MediLink Therapeutics and F.Hoffmann-La Roche Ltd. forged a license agreement and collaboration to develop a next-generation ADC, YL211.

Antibody Drug Conjugates Market Segmentations:

By Application

• Blood Cancer
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
• Breast Cancer
• Urothelial Cancer & Bladder Cancer
• Other Cancer

By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

By Target

• HER2
• CD22
• CD30
• Others

By Technology

• Type
  • Cleavable Linker
  • Non-cleavable Linker
  • Linkerless
• Linker Technology Type
  • VC
  • Sulfo-SPDB
  • VA
  • Hydrazone
  • Others
• Payload Technology
  • MMAE
  • MMAF
  • DM4
  • Camptothecin
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• MEA